Home > Insider Trading > Filing (0000903423-16-001321)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674416	Crispr Therapeutics Ag	CRSP	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1595117	Simeon George	C/O S.r. One, Limited 161 Washington Street, Suite 500 Conshohocken PA 19428		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2016-10-24	2,942,560	$0.00	2,942,560	No	4	C	Indirect	See explanation of responses
Common Shares	Acquisiton	2016-10-24	211,567	$0.00	3,154,127	No	4	C	Indirect	See explanation of responses
Common Shares	Acquisiton	2016-10-24	66,500	$14.00	3,220,627	No	4	P	Indirect	See explanation of responses

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See explanation of responses
No	4	C	Indirect	See explanation of responses
No	4	P	Indirect	See explanation of responses

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Series A-3 Preferred Shares	Disposition	2016-10-24	2,942,560	$0.00	2,942,560	$0.00
Common Shares	Series B Preferred Shares	Disposition	2016-10-24	211,567	$0.00	211,567	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

On October 24, 2016, S.R. One, Limited ("S.R. One") acquired 66,500 common shares of the Issuer ("Common Shares") at a price of $14.00 per share in connection with the Issuer's initial public offering.
These shares are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Simeon J. George (the "Reporting Person") is a Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. The Reporting Person disclaims beneficial ownership of all the shares herein and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his proportionate pecuniary interest therein, if any.
On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering
Not applicable.